Position in LXEO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$17,260,713
New position
Shares Held
3,007,093
first reported quarter
Ownership
3.83%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Mar 31, 2026VANGUARD CAPITAL MANAGEMENT LLC holds $38,435,031,590 across 449 Biotechnology names. LXEO ranks #161 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
16,512,810 | $7,373,630,177 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
6,654,913 | $5,141,851,980 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
5,946,706 | $1,967,586,614 | |
| 4 | INSM |
INSMED Inc
|
9,642,131 | $1,576,681,261 | |
| 5 | MRNA |
Moderna, Inc.
|
22,872,458 | $1,161,920,866 | |
| 6 | INCY |
Incyte Corp
|
10,930,066 | $1,028,737,811 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
8,362,284 | $813,232,119 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
7,759,495 | $576,220,098 |
All Filings in LXEO
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $17,260,713 | 3,007,093 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||